<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02719197</url>
  </required_header>
  <id_info>
    <org_study_id>AC-083-101</org_study_id>
    <secondary_id>2015-005012-15</secondary_id>
    <nct_id>NCT02719197</nct_id>
  </id_info>
  <brief_title>First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders</brief_title>
  <official_title>Single-center, Double-blind, Placebo-controlled, Randomized, Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics (Including Food Effect), and Pharmacodynamics of an Oral Drug for Neurological Disorders in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this first-in-man study is to investigate whether a new drug for
      neurological disorders is safe and well-tolerated when administered orally to healthy male
      adults
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 19, 2016</start_date>
  <completion_date type="Actual">December 1, 2016</completion_date>
  <primary_completion_date type="Actual">December 1, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>From baseline to end of study (EOS) (up to Day 12)</time_frame>
    <description>Treatment-emergent AEs and treatment emergent serious AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in supine blood pressure</measure>
    <time_frame>From baseline to EOS (up to Day 12)</time_frame>
    <description>Supine blood pressure (mmHg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in electrocardiogram (ECG) variables</measure>
    <time_frame>From baseline to EOS (up to Day 12)</time_frame>
    <description>ECG variables are to be recorded at rest using a standard 12-lead ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in pulse rate</measure>
    <time_frame>From baseline to EOS (up to Day 12)</time_frame>
    <description>Pulse rate (bpm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) following single oral ascending doses</measure>
    <time_frame>From pre-dose on Day 1 to up to Day 12</time_frame>
    <description>Cmax is derived from the observed plasma concentration-time curves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (tmax) following single oral ascending doses</measure>
    <time_frame>From pre-dose on Day 1 to up to Day 12</time_frame>
    <description>Tmax is derived from the observed plasma concentration-time curves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life [t(1/2)] following single oral ascending doses</measure>
    <time_frame>From pre-dose on Day 1 to up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) following single oral ascending doses</measure>
    <time_frame>From pre-dose on Day 1 to up to Day 12</time_frame>
    <description>AUC is defined for the time intervals from zero to time t of the last measured concentration above the limit of quantification, from zero to infinity and from zero to 24 h after study drug administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>AC-083, Single Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AC-083 administered at different single dose levels in a sequential manner, and in a maximum of 9 dose levels starting from 1 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each dose level will be investigated in a new group of 8 healthy male subjects (6 on active drug and 2 on placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Single Ascending Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo administered as single ascending doses in parallel to AC-083</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-083</intervention_name>
    <description>Hard gelatin capsules for oral administration formulated at a strengths of 1, 10 and 100 mg</description>
    <arm_group_label>AC-083, Single Ascending Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules matching AC-083 capsules</description>
    <arm_group_label>Placebo, Single Ascending Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Healthy on the basis of physical examination, electrocardiogram and laboratory tests.

          -  A subject who has a female partner of childbearing potential or a pregnant partner
             agrees to use a condom in combination with spermicide or a condom, respectively, from
             screening, during the entire study, and for at least 3 months after (the last) study
             drug intake

          -  Body mass index (BMI) of 18.0 to 29.9 kg/m2 (inclusive) at screening and Day -1.

          -  Systolic blood pressure (SBP) 100-140 mmHg, diastolic blood pressure (DBP) 50-90 mmHg,
             and pulse rate 50-90 bpm (inclusive), measured after 5 min in the supine position at
             screening and at Day -1.

        Exclusion Criteria:

          -  History or clinical evidence of any disease and/or existence of any surgical or
             medical condition which might interfere with the absorption, distribution, metabolism
             or excretion of the study treatment

          -  Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal
             reactions

          -  Any cardiac condition or illness with a potential to increase the cardiac risk of the
             subject based on medical history, physical examination, or electrocardiogram (ECG)
             evaluations

          -  Any circumstances or conditions, which, in the opinion of the Investigator, may affect
             full participation in the study or compliance with the protocol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2016</study_first_submitted>
  <study_first_submitted_qc>March 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2016</study_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

